Detalhe da pesquisa
1.
Ibrutinib plus Bendamustine and Rituximab in Untreated Mantle-Cell Lymphoma.
N Engl J Med
; 386(26): 2482-2494, 2022 06 30.
Artigo
em Inglês
| MEDLINE | ID: mdl-35657079
2.
High transferrin saturation predicts inferior clinical outcomes in patients with myelodysplastic syndromes.
Haematologica
; 108(2): 532-542, 2023 02 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-35979720
3.
Overall survival in lower IPSS risk MDS by receipt of iron chelation therapy, adjusting for patient-related factors and measuring from time of first red blood cell transfusion dependence: an MDS-CAN analysis.
Br J Haematol
; 179(1): 83-97, 2017 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-28677895
4.
A predictive model of response to erythropoietin stimulating agents in myelodysplastic syndrome: from the Canadian MDS patient registry.
Ann Hematol
; 96(12): 2025-2029, 2017 Dec.
Artigo
em Inglês
| MEDLINE | ID: mdl-28975386
5.
ITACA: A new validated international erythropoietic stimulating agent-response score that further refines the predictive power of previous scoring systems.
Am J Hematol
; 92(10): 1037-1046, 2017 Oct.
Artigo
em Inglês
| MEDLINE | ID: mdl-28675513
6.
Outcomes of Allogeneic Hematopoietic Cell Transplantation in Patients with Myelofibrosis with Prior Exposure to Janus Kinase 1/2 Inhibitors.
Biol Blood Marrow Transplant
; 22(3): 432-40, 2016 Mar.
Artigo
em Inglês
| MEDLINE | ID: mdl-26493563
7.
Treatment of adults with BCR-ABL negative acute lymphoblastic leukaemia with a modified paediatric regimen.
Br J Haematol
; 146(1): 76-85, 2009 Jun.
Artigo
em Inglês
| MEDLINE | ID: mdl-19438471
8.
Iron overload in myelodysplastic syndromes: Evidence based guidelines from the Canadian consortium on MDS.
Leuk Res
; 74: 21-41, 2018 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-30286330
9.
The immunomodulatory agents lenalidomide and thalidomide for treatment of the myelodysplastic syndromes: a clinical practice guideline.
Crit Rev Oncol Hematol
; 85(2): 162-92, 2013 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-22901762
10.
Treatment of older patients with acute myeloid leukemia (AML): a Canadian consensus.
Am J Blood Res
; 3(2): 141-64, 2013.
Artigo
em Inglês
| MEDLINE | ID: mdl-23675565
11.
Sunitinib malate in patients with intermediate-2 or high-risk myelodysplastic syndrome or chronic myelomonocytic leukemia.
Leuk Lymphoma
; 55(11): 2669-71, 2014 Nov.
Artigo
em Inglês
| MEDLINE | ID: mdl-24611649